MedTrace Logo

Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel

NCT01456546 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2013-07-03

No results posted yet for this study

Summary

The aim of this study is to investigate if the genetic variant CYP2C19\*17 affects the pharmacokinetics of proguanil and clopidogrel.

Conditions

  • CYP2C19 Genotypes

Interventions

DRUG

Proguanil

2x350 mg Malarone followed by 3 days of blood- and urine sampling

DRUG

Clopidogrel

2x300 mg Plavix followed by 7 hours days of blood sampling

Sponsors & Collaborators

  • University of Southern Denmark

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01456546 on ClinicalTrials.gov